Related Experiment Video

Updated: Aug 6, 2025

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.2K

Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer

Natalie I Vokes1,2, Kelsey Pan3, Xiuning Le4

  • 1Department of Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.

Therapeutic Advances in Medical Oncology
|March 23, 2023
PubMed

Insights

Targeted therapies are expanding for advanced non-small cell lung cancer. This review examines immune checkpoint inhibitors (ICIs) efficacy and safety across oncogene-driven lung cancer subtypes to guide treatment selection.

Area of Science:

  • Oncology
  • Genetics
  • Immunology

Background:

  • The field of targeted therapy for advanced metastatic non-small cell lung cancer (NSCLC) is rapidly evolving.
  • An increasing number of actionable driver alterations are being identified, leading to new drug approvals.
  • Targeted therapies may soon be available for a majority of lung adenocarcinoma patients.

Purpose of the Study:

  • To review current clinical data on immune checkpoint inhibitors (ICIs) in oncogene-driven NSCLC.
  • To assess the efficacy and safety of ICIs as monotherapy or in combination with chemotherapy or radiation.
  • To explore strategies for enhancing ICI efficacy in this patient population.

Main Methods:

  • Systematic review of clinical trial data and published literature.
  • Analysis of efficacy outcomes (response rates, progression-free survival, overall survival).
  • Evaluation of safety profiles, including toxicities of combined or sequential ICI and targeted therapy.

Main Results:

  • Efficacy data for ICIs in various oncogene-driven NSCLC subtypes are presented.
  • Safety data regarding the combination or sequencing of ICIs with targeted therapies are discussed.
  • Potential strategies to improve ICI effectiveness in oncogene-driven NSCLC are identified.

Conclusions:

  • Understanding ICI efficacy and safety across different oncogene-driven NSCLC subtypes is crucial for optimal treatment selection and sequencing.
  • The review provides a comprehensive overview to guide clinicians in utilizing ICIs effectively.
  • Further research into enhancing ICI efficacy in this setting is warranted.
Keywords:
immunotherapylung canceroncogeneprecision oncology

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

908

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
600
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
460